193 related articles for article (PubMed ID: 34475524)
1. Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children.
Pincez T; Santiago R; Bittencourt H; Louis I; Bilodeau M; Rouette A; Jouan L; Landry JR; Couture F; Richer J; Teira P; Duval M; Cellot S
Bone Marrow Transplant; 2021 Dec; 56(12):2981-2989. PubMed ID: 34475524
[TBL] [Abstract][Full Text] [Related]
2. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
4. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
Bacher U; Haferlach T; Fehse B; Schnittger S; Kröger N
ScientificWorldJournal; 2011 Feb; 11():310-9. PubMed ID: 21298222
[TBL] [Abstract][Full Text] [Related]
8. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
9. The mythological chimera and new era of relapse prediction post-transplant.
Ciurea SO; Kothari A; Sana S; Al Malki MM
Blood Rev; 2023 Jan; 57():100997. PubMed ID: 35961800
[TBL] [Abstract][Full Text] [Related]
10. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
11. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
12. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
13. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
14. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
16. Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Semchenkova A; Brilliantova V; Shelikhova L; Zhogov V; Illarionova O; Mikhailova E; Raykina E; Skorobogatova E; Novichkova G; Maschan A; Maschan M; Popov A
Cytometry B Clin Cytom; 2021 Sep; 100(5):568-573. PubMed ID: 33369016
[TBL] [Abstract][Full Text] [Related]
17. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation.
Waterhouse M; Pfeifer D; Duque-Afonso J; Follo M; Duyster J; Depner M; Bertz H; Finke J
Clin Chem Lab Med; 2019 Apr; 57(5):641-647. PubMed ID: 30457973
[TBL] [Abstract][Full Text] [Related]
18. Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation.
Elmaagacli AH
Int J Hematol; 2002 Aug; 76 Suppl 2():204-5. PubMed ID: 12430926
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
20. [Significance of Monitoring Minimal Residual Disease by Flow Cytometry in Acute Leukemia Patients Underwent Nonmyeloablative Allo-HSCT].
Liu XX; Liu TQ; Guo M; Sun QY; Qiao JH; Hu KX; Li BX; Yao B; Yu CL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):873-879. PubMed ID: 28641652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]